Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 12/20 | 0.67 |
| ▸ | TLR2 | O60603 | 12/20 | 0.67 |
| ▸ | MAOA | P21397 | 8/20 | 0.67 |
| ▸ | MAOB | P27338 | 8/20 | 0.67 |
| ▸ | FBP1 | P09467 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619911 | 0.81 | TLR4 (0.70) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL4619916 | 0.81 | TLR4 (0.70) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL510222 | 0.81 | MAOA (1.00) | TLR4TLR2MAOAMAOB | |
| SCHEMBL510223 | 0.81 | MAOA (1.00) | TLR4TLR2MAOAMAOB | |
| SCHEMBL510208 | 0.79 | TLR4 (1.00) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL510207 | 0.79 | TLR4 (1.00) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL4683688 | 0.78 | CCNB2 (0.65) | MAOAMAOB | |
| SCHEMBL3175679 | 0.78 | LMNA (0.54) | — | |
| SCHEMBL3175689 | 0.78 | LMNA (0.54) | — | |
| SCHEMBL4683690 | 0.78 | CCNB2 (0.65) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016172545-A1 | CASTRATION-RESISTANT PROSTATE CANCER | NUTECH VENTURES (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | UGDH, G6PD, DPYD | TLR4 4614/4885TLR2 4703/4885MAOA 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.